Systematic Review

Cystic Fibrosis in the SARS-CoV-2/COVID-19 Pandemic

Hannah R. Mathew; May Y. Choi; Michael D. Parkins; Marvin J. Fritzler

Disclosures

BMC Pulm Med. 2021;21(173) 

In This Article

Conclusions

Although individuals with CF are at risk of acute exacerbations of chronic lung disease, often precipitated by respiratory tract viral infections, published evidence to date indicates that incidence rates of SARS-CoV-2 infection may be lower in CF than the general population. Furthermore, data to date suggests that COVID-19 disease outcomes in individuals with CF may not be as severe as those brought on by H1N1 infection. However, there is evidence that some subsets within the CF population, including those post-transplantation, may experience a more severe clinical course. The limited cases of SARS-CoV-2 infection among the CF population is likely due to several factors that include effective physical and social distancing and the effective use of learned principles and practices of infection control stressed as parts of routine CF care. Other factors that are likely at play include altered expression of ACE, ACE2, and CFTR; and the use of medications with anti-viral effects.

processing....